AI-Designed Protein Vehicles Outperform Lipid Nanoparticles for RNA and CRISPR Delivery
核心洞察
Researchers at Helmholtz Munich (搜索) and TUM developed Synthetic Transfer Vehicles (STVs), an AI-designed protein-based RNA delivery platform that outperformed lipid nanoparticles in cell culture.
The lead construct STV-C8 (搜索) required more than 10,000-fold less mRNA than LNPs formulated with ALC-0315 to achieve equivalent reporter expression in HEK293T cells.
STV-C8 (搜索) delivered Cas9 (搜索) mRNA and guide RNAs into patient-derived Duchenne muscular dystrophy (搜索) muscle cells, restoring the dystrophin (搜索) reading frame, and achieved on-target editing in a pig model.
Researchers at Helmholtz Munich (搜索) and the Technical University of Munich (搜索) (TUM) have developed a new class of RNA delivery vehicles built from AI-designed protein assemblies that, in preclinical experiments, outperformed lipid nanoparticles (LNPs) in several cell systems and delivered CRISPR gene-editing cargo in patient-derived muscle cells and a pig model. The platform, called Synthetic Transfer Vehicles (STVs), is described in a study published September 3, 2026 in Nature, led by corresponding authors Christoph Gruber, Florian Giesert, and Wolfgang Wurst.
The work addresses a central limitation in RNA therapeutics: efficient delivery beyond tissues readily reached by current LNP systems. Unlike viral vectors, the lead construct STV-C8 (搜索) is built from synthetic protein components and can potentially be retargeted without redesigning its core architecture.
A Bottom-Up Approach to RNA Transport
The STV platform combines an AI-designed protein scaffold with membrane-binding, vesicle-release, and RNA-binding domains. The researchers combined naturally occurring protein building blocks with synthetic protein structures designed using generative AI, constructing an RNA transporter "from the ground up."
"We did not want to recreate nature, but to design new structures for a specific task: the efficient delivery of RNA," said Dr. Christoph Gruber, team leader at the Institute of Stem Cell Research (ISF) and co-first author of the study.
The team tested more than one hundred variants, and surprisingly, protein structures with non-natural geometries performed particularly well. The lead construct, STV-C8 (搜索), forms approximately 110-nanometer vesicles that package RNA cargo and can be retargeted to different cell types using computationally designed receptor-binding proteins.
"The fact that a structure that differs so markedly from natural viral capsids works particularly well was a key finding for us," said Dr. Maren Kirstin Schuhmacher, postdoctoral researcher at the ISF and co-first author. "It demonstrates the potential of using AI to systematically expand the protein design space."
Superior Efficiency Compared with Lipid Nanoparticles
In HEK293T cells, STV-C8 (搜索) required more than 10,000-fold less mRNA than LNPs formulated with the clinical ionizable lipid ALC-0315 to achieve equivalent reporter expression. The platform also delivered RNA into primary human monocytes, retinal organoids, and mouse astrocytes — cell types in which LNP performance was more limited.
"This modularity is particularly important to us because it allows us to adapt the transporter to different applications and target cells," said Dr. Florian Giesert, group leader for Gene Editing at the ISF.
Therapeutic Proof-of-Concept in Duchenne Muscular Dystrophy
For therapeutic proof-of-concept, STV-C8 (搜索) delivered Cas9 (搜索) mRNA and guide RNAs targeting dystrophin (搜索) exon 51 into patient-derived skeletal muscle cells carrying a DMD-associated deletion, restoring the reading frame at the DNA level. The researchers also confirmed on-target editing after intramuscular administration in a single German Landrace pig, although the large-animal experiment was an initial proof-of-concept with n=1.
Additional experiments showed delivery of Cas13d (搜索) RNA machinery into human lung cells, reducing SARS-CoV-2 (搜索) replication, and delivery of Ascl1 mRNA with evidence of neuronal reprogramming activity.
In Vivo Biodistribution and Safety Observations
Following intravenous administration in mice, STV-C8 (搜索) led to expression of the delivered RNA primarily in the lungs, and the researchers found no evidence of immunological or toxic side effects. Short-term mouse studies showed no significant increases in inflammatory cytokines, histopathological abnormalities, or body-weight changes over three days.
However, longer-term safety, dose-escalation, biodistribution, and repeat-dosing studies have not yet been reported. STV-C8 (搜索) remains an experimental system, and before it can be used medically, the researchers will need to investigate how the vehicles can be directed specifically to particular cell types and how they distribute throughout the body.
Next Steps Toward Translation
The platform remains at an early preclinical stage, with no IND filed and no clinical trial registered. Helmholtz Munich (搜索) has secured EUR 3.1 million in German government funding under the GO-Bio Next program to support further preclinical development and potential formation of a spin-off company.
"With STV-C8 (搜索), we have created a platform that we can now further develop for a range of therapeutic applications," said Prof. Wolfgang Wurst, Emeritus of Excellence at Helmholtz Munich (搜索) and TUM and last author of the publication.
The study was first posted as a Research Square preprint in October 2024, with the peer-reviewed version now published in Nature (Schuhmacher et al., 2026, DOI: 10.1038/s41586-026-10952-3).